News

Jerry Durso Takes Over as Chairman of Altimmune's Board

Jerry Durso Takes Over as Chairman of Altimmune's Board

Aligning Leadership with Strategic Goals at Altimmune

In a celebrated move, Altimmune, Inc. has officially appointed Jerry Durso as Chairman of its Board of Directors. With extensive commercial expertise, Mr. Durso's leadership comes during an exciting phase of development for Altimmune, particularly regarding its innovative drug pemvidutide, which targets metabolic dysfunction-associated steatohepatitis (MASH).

Succession Planning and Transition

The leadership change, effective August 12, 2025, marks a significant moment for the company as it transitions towards advanced clinical phases. Previously held by Mitchel Sayare, Ph.D., Mr. Durso's role will now support the company's aim of preparing for Phase 3 development of pemvidutide, a promising therapeutic for treating MASH. This strategic transition underscores the Board's ongoing evaluation of its leadership needs to align with evolving business goals.

Building on Past Success

Vipin K. Garg, Ph.D., President and CEO of Altimmune, expressed enthusiasm for Mr. Durso's appointment, emphasizing the impactful contributions he has already made since joining the Board earlier this year. “Jerry's adept understanding of commercial dynamics will be pivotal as we continue our journey in the clinical stage,” said Dr. Garg.

Innovative Therapeutics for Tomorrow

Altimmune is making significant strides in the biopharmaceutical landscape, focusing on developing novel peptide-based therapies for liver and cardiometabolic diseases. Pemvidutide stands out as a game changer—a GLP-1/glucagon dual receptor agonist designed specifically to combat conditions like MASH and obesity. The promising topline data from the IMPACT trial has fortified its potential, showcasing the necessity for adept leadership during this crucial phase.

Experience That Counts

Jerry Durso brings to his role a wealth of experience amassed over three decades in the life sciences sector. Before his appointment, he served as the CEO at Intercept Pharmaceuticals, where he played a critical role in developing the company’s rare liver disease portfolio, leading to its acquisition by Alfasigma. His previous positions at Sanofi also reflect a solid foundation in the pharmaceutical industry, demonstrating his capability to navigate corporate and commercial challenges effectively.

Commitment to Patients and Stakeholders

During this transitional period, Mr. Durso is committed to enhancing Altimmune’s strategies not only to advance pemvidutide but also to create sustainable value for all stakeholders involved. He recognizes the importance of supporting the patient community through access to innovative therapies—a mission integral to Altimmune's ethos.

Looking Ahead: Phase 3 Development

As Altimmune gears up for an End-of-Phase 2 Meeting with the FDA planned for the upcoming fourth quarter, the board’s renewed focus on corporate development is timely. Dr. Sayare's continued presence on the Board as an Independent Director ensures a blend of new leadership and established expertise, fostering a synergistic approach to the challenges ahead.

About Altimmune

Altimmune stands as a beacon of innovation in therapeutic development, focusing on addressing significant unmet needs in liver and cardiometabolic health. Pemvidutide, the company’s core program, exemplifies its commitment to pioneering effective treatments.

Frequently Asked Questions

Who is the new Chairman of Altimmune?

Jerry Durso has been appointed as the new Chairman of Altimmune's Board of Directors.

What is pemvidutide?

Pemvidutide is a novel peptide-based therapeutic designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and other related conditions.

How does Jerry Durso's experience benefit Altimmune?

Durso brings over 30 years of leadership experience in the life sciences, enhancing corporate strategies and guiding the company through clinical development phases.

What is Altimmune's focus?

Altimmune is dedicated to developing peptide-based therapeutics aimed at liver and cardiometabolic diseases, particularly through its lead program, pemvidutide.

What are the next steps for Altimmune?

The company is set to engage with the FDA for an End-of-Phase 2 Meeting, targeting advancements in the development of pemvidutide.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 63

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 97

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 36

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 50

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 63

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover AM Best's New Bookstore for Insurance Insights

Updated Category News Views 92

AM Best Unveils Innovative Bookstore for Insurance Readers AM Best recently launched the AM Best’s Bookstore, a unique digital platform designed for those interested in deeper insights into the insurance sector. This bookstore serves as a central hub for information on newly published books that cover a wide range of topics pertinent to the insurance industry....

Continue Reading
Aurora Mobile Hits a Milestone with Strong Q2 Financials

Updated Category News Views 174

Aurora Mobile Reports Impressive Second Quarter Financial Results Aurora Mobile Limited, recognized for its customer engagement and marketing technology services, has revealed its financial metrics for the second quarter of 2025. This quarter has marked a groundbreaking achievement with the company recording its inaugural quarterly net income under U.S. GAAP. Financial...

Continue Reading
Meta Platforms' Competitive Edge in Media and Services Sector

Updated Category News Views 279

Understanding Meta Platforms in its Industry Context In the fast-paced realm of Interactive Media & Services, comprehensive analysis is vital for both investors and market analysts. This article dives into an industry comparison, focusing on Meta Platforms (NASDAQ: META) along with its prominent competitors. By evaluating crucial financial indicators, market standings,...

Continue Reading
Investigation by Rosen Law Firm for Kaspi.kz Investors

Updated Category News Views 88

Rosen Law Firm's Investigation of Kaspi.kz Security Claims The Rosen Law Firm, globally recognized for protecting investor rights, has launched an investigation regarding potential securities claims for shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This investigation stems from serious allegations that Kaspi.kz may have disseminated misleading business...

Continue Reading
Praxis Precision Medicines to Showcase Innovations This Fall

Updated Category News Views 158

Upcoming Investor Conferences for Praxis Precision Medicines Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a dynamic entity in the field of biopharmaceuticals, has an exciting roster of events lined up this fall. The company is dedicated to developing therapies aimed at addressing central nervous system (CNS) disorders that are driven by imbalances in neuronal...

Continue Reading